Traders should monitor for downward price pressure and potential negative catalysts; such concentrated selling by top executives, especially the CEO and R&D lead, often precedes disappointing developments in clinical-stage biotechs. Consider hedging long positions or reducing exposure ahead of upcoming data readouts or earnings.
Price Chart
Executive Summary
Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a coordinated cluster of derivative exercises and open-market sales over a 7-day window, realizing $7.5M in proceeds. The transactions include both non-cash exercises and direct sales at prices between $80.70 and $81.48, with the CEO and CFO selling over $4.7M and $1.2M respectively.
Key Financial Metrics
Key Facts
- CEO Garcia Marino sold $3.51M in shares and exercised derivatives for 182,618 shares (partially non-cash), realizing $1.22M in cost basis.
- EVP Randhawa Simrat sold $2.76M and exercised derivatives for 15,996 shares with $67,503 in cost basis.
- Chief Accounting Officer Carr sold $1.28M and exercised 16,182 shares with $289,334 in cost basis.
- Total open-market sales: $7.5M across 3 insiders on March 12, coinciding with peak stock price activity.
- All sales occurred within a 4-day window at prices near $81, representing a coordinated liquidity event.
Financial Impact
$7.5M in insider sales over 7 days, representing 0.21% of $3.5B market cap — significant for a biotech of this size.
Risk Factors
- Insider selling may signal lack of confidence in near-term clinical or financing outcomes.
- Potential for follow-on dilution given cashout of executives ahead of possible capital raise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (11 trades, 7d window) | cluster-DNTH-1773782600349 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access